HCW Biologics, Inc. (HCWB)

HCW Biologics Inc.'s stock price has significantly declined in the past six months. As of November 19, 2025, the share price was $1.99, a 94.75% decrease from $37.89 on November 20, 2024. The stock price has decreased by approximately 90.88% to 91.27% over the last year and saw a 75.63% decrease over the past six months. In November 2024, HCW Biologics announced the pricing of a $6.9 million registered direct offering and a concurrent private placement, and the company's stock jumped following a license agreement for an immunotherapeutic product candidate.

Seasonal tools exist to analyze stock movements and identify repeating trends on an annual basis for HCWB. However, specific details or patterns regarding the demand seasonality for HCW Biologics Inc.'s products and services are not available in the provided search results.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to disrupt the link between chronic inflammation and age-related diseases. Their lead product candidates include HCW9218, a bifunctional molecule in Phase 1b/2 trials for pancreatic cancer; HCW9302, an IL-2 fusion protein complex in Phase 1 for autoimmune diseases; HCW9201, a cell-based therapy in Phase I clinical trials for treating patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic for adoptive cell therapy in cancer treatment. The company also has license agreements with Wugen Inc. and WY Biotech Co., Ltd. and utilizes its TOBI discovery platform to generate multi-functional fusion molecules.

HCW Biologics Inc. is headquartered in Miramar, Florida, United States, with a primary focus on discovering and developing immunotherapies within the United States.

Direct information detailing HCW Biologics Inc.'s brand reputation is not available in the provided search results. HCW Biologics has a consensus rating of "Hold" from Wall Street analysts, based on one buy rating and one sell rating in the last twelve months. The company's MarketRank™ score indicates it scored higher than 50% of companies evaluated by MarketBeat.

HCW Biologics Inc. has institutional ownership, with 16 institutional owners and shareholders holding between 2.96% and 6.69% of the company's stock. Major institutional owners include DRW Securities, LLC, Vanguard Group Inc, and Geode Capital Management, Llc. Insider ownership stands at 34.43%, with 0.74 million shares held by insiders. Recent insider activity includes direct purchases by directors and officers in May 2025.